PTGFRN and malignant biphasic mesothelioma: The resulting antibody drug conjugate (8C7‐ADC) was first examined in vitro for its ability to inhibit the proliferation of PTGFRN‐expressing cell lines such as epidermoid carcinoma (A431), biphasic mesothelioma (MSTO‐211H), and paediatric medulloblastoma (DAOY).